A Conversation with Writer and Troublemaker Carl Elliott, Parts I & II
By Misha Angrist,
PLOS Medicine/GenomeBoy
| 12. 02. 2011
In 2009 I attended the annual meeting of the American Society for Bioethics and Humanities. The keynote speaker was Carl Elliott. I knew he was a Professor at the Center for Bioethics at the University of Minnesota and I knew he wrote for The New Yorker. I had assigned his piece on the lives of human research participants, Guinea-Pigging, to both my science writing and genomics-in-society classes. But none of that prepared me for his speech, which was eloquent, thoughtful, accusatory, profane, and above all, funny as hell. In 25 years of academic conferences, I can’t recall hearing another talk that made me laugh until I cried.
There were hilarious vignettes from Elliott’s South Carolina childhood and jabs at “bioethicists for hire” (including many in the audience–at times it was almost as though the National Cattlemen’s Beef Association had invited a strident and acerbic member of PETA to deliver its keynote). But in between was a question: why weren’t more of us doing what he was doing? Why weren’t we investigating egregious, troubling or even benign-but-fascinating...
Related Articles
Cathy Tie seems to be good at starting businesses but not so dedicated to maintaining them. CGS, like many others, first heard of her thanks to Caiwei Chen and Antonio Regalado in MIT Technology Review, May 2025, as the partner (perhaps bride) of the notorious Chinese scientist He Jiankui, described in the headline as “China’s Frankenstein.” He prefers “Chinese Darwin.” She ran his Twitter account for a while, contributing such gems as:
Get in luddite, we’re going gene editing...
By Laura DeFrancesco, Nature Biotechnology | 03.17.2026
The first gene editors designed to fix genetic lesions in mutation-agnostic ways are poised to enter the clinic. Tessera Therapeutics and Alltrna, two Flagship Pioneering-funded companies, are gearing up to test novel genetic medicines in humans. Tessera received regulatory clearance...
By Darren Incorvaia, Fierce Biotech | 03.11.2026
A new method for safely inserting large chunks of DNA into genomes has now measured up in mice, potentially paving the way for the next generation of gene editing medicines.
The approach, which is described in a Nature paper...
By Carolyn Riley Chapman and Nirvan Bhatia, Hastings Bioethics Forum | 03.12.2026
Last year, researchers saved an infant named KJ from a life-threatening rare metabolic disorder using a customized gene editing therapy. This was the first time that an individualized gene therapy was used to treat a human patient, and it has...